These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 1085172

  • 21. [Therapeutic evolution of 63 cases of recent acute myeloblastic leukemias].
    Fiere D, Bryon PA, Dechavanne M, Guyon JM, Kahi S, Revol L.
    Lyon Med; 1971 Feb 14; 225(3):225-8. PubMed ID: 5280026
    [No Abstract] [Full Text] [Related]

  • 22. Daunorubicin in the therapy of acute granulocytic leukemia.
    Weil M, Glidewell OJ, Jacquillat C, Levy R, Serpick AA, Wiernik PH, Cuttner J, Hoogstraten B, Wasserman L, Ellison RR, Gailani S, Brunner K, Silver RT, Rege VB, Cooper MR, Lowenstein L, Nissen NI, Haurani F, Blom J, Boiron M, Bernard J, Holland JF.
    Cancer Res; 1973 May 14; 33(5):921-8. PubMed ID: 4512953
    [No Abstract] [Full Text] [Related]

  • 23. [Late results of the treatment of acute granulocytic leukemia in adults].
    Perilov AA, Volkova MA, Frenkel' MA.
    Ter Arkh; 1989 May 14; 61(7):8-11. PubMed ID: 2588148
    [Abstract] [Full Text] [Related]

  • 24. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May 14; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

  • 25. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y.
    Semin Hematol; 1996 Oct 14; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [Abstract] [Full Text] [Related]

  • 26. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.
    Ann Hematol; 2004 Nov 14; 83(11):696-703. PubMed ID: 15322763
    [Abstract] [Full Text] [Related]

  • 27. Prognosis of acute leukaemia in adults.
    Penington DG, Keating MJ.
    Med J Aust; 1974 Jun 29; 1(26):1031-5. PubMed ID: 4527947
    [No Abstract] [Full Text] [Related]

  • 28. [Letter: Polychemotherapeutic treatment in acute myeloblastic leukemia].
    Fiere D, Bryon PA, Martin C, Revol L.
    Nouv Presse Med; 1973 Dec 15; 2(45):3046. PubMed ID: 4544125
    [No Abstract] [Full Text] [Related]

  • 29. [Treatment of acute myeloid leukemia in adults with a combination of daunomycin and cytosine-arabinoside].
    Brincker H.
    Ugeskr Laeger; 1972 Oct 16; 134(42):2195-200. PubMed ID: 4563112
    [No Abstract] [Full Text] [Related]

  • 30. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J, Mathé G, Hayat M.
    Bull Cancer; 1974 Oct 16; 61(3):411-8. PubMed ID: 4533741
    [No Abstract] [Full Text] [Related]

  • 31. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
    Bär BM, de Witte T, de Pauw BE, Haanen C.
    Neth J Med; 1990 Feb 16; 36(1-2):19-24. PubMed ID: 2314517
    [Abstract] [Full Text] [Related]

  • 32. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM.
    Cancer; 2004 Mar 15; 100(6):1179-85. PubMed ID: 15022284
    [Abstract] [Full Text] [Related]

  • 33. [Trial treatment of acute myeloblastic leukemia with the cytosine arabinoside-cyclophosphamide association. (Apropos of 30 cases)].
    Bauters F, Lerche B, Samsoen J, Goudemand M.
    Therapeutique; 1972 Apr 15; 48(4):303-8. PubMed ID: 4507025
    [No Abstract] [Full Text] [Related]

  • 34. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C, Hassan HT.
    Leuk Res; 2006 Mar 15; 30(3):296-302. PubMed ID: 16112192
    [Abstract] [Full Text] [Related]

  • 35. Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias.
    Fière D, Campos L, Van HV, Guyotat D, Archimbaud E, Extra JM, Coiffier B, Viala JJ, Bryon PA, Milan JJ.
    Cancer Treat Rep; 1986 Feb 15; 70(2):285-6. PubMed ID: 3456272
    [Abstract] [Full Text] [Related]

  • 36. Induction therapy and intensive consolidation with daunorubicin, cytosine arabinoside, and 6-thioguanine in adult acute nonlymphoblastic leukemia.
    Cassileth PA, Kahn SB, Silber R, Weiler C.
    Cancer Clin Trials; 1981 Feb 15; 4(2):125-8. PubMed ID: 7249250
    [Abstract] [Full Text] [Related]

  • 37. Treatment of AGL.
    Lee SL, Rosner F.
    Arch Intern Med; 1969 Feb 15; 123(2):205-6. PubMed ID: 5249563
    [No Abstract] [Full Text] [Related]

  • 38. Development of pulmonary aspergillomas coinciding with induction of remission in acute myeloid leukaemia.
    Brincker H, Hansen PB.
    Dan Med Bull; 1974 Mar 15; 21(1):37-40. PubMed ID: 4524494
    [No Abstract] [Full Text] [Related]

  • 39. Treatment of the acute leukemias.
    Bernard J, Jacquillat C, Weil M.
    Semin Hematol; 1972 Apr 15; 9(2):181-91. PubMed ID: 4553226
    [No Abstract] [Full Text] [Related]

  • 40. DNA synthesis in leukemic cells under the action of cytotoxic agents in vitro and in vivo.
    Wilmanns W.
    Natl Cancer Inst Monogr; 1971 Dec 15; 34():153-9. PubMed ID: 5291099
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.